Insmed Incorporated (NASDAQ:INSM) Expected to Earn FY2025 Earnings of ($3.54) Per Share

Insmed Incorporated (NASDAQ:INSMFree Report) – Stock analysts at HC Wainwright reduced their FY2025 earnings estimates for Insmed in a research report issued on Wednesday, May 29th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings of ($3.54) per share for the year, down from their prior estimate of ($3.52). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.52) per share. HC Wainwright also issued estimates for Insmed’s FY2026 earnings at ($2.37) EPS, FY2027 earnings at ($0.72) EPS and FY2028 earnings at $1.19 EPS.

Other equities analysts also recently issued research reports about the company. Wolfe Research started coverage on Insmed in a report on Thursday, February 15th. They issued an “outperform” rating and a $42.00 price objective on the stock. StockNews.com upgraded shares of Insmed from a “sell” rating to a “hold” rating in a report on Tuesday, May 14th. Mizuho upped their price objective on shares of Insmed from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, May 13th. Stifel Nicolaus increased their target price on shares of Insmed from $39.00 to $67.00 and gave the stock a “buy” rating in a research report on Friday. Finally, The Goldman Sachs Group boosted their price target on Insmed from $49.00 to $74.00 and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.38.

Check Out Our Latest Report on Insmed

Insmed Price Performance

Shares of INSM stock opened at $55.05 on Friday. Insmed has a fifty-two week low of $18.31 and a fifty-two week high of $58.82. The stock’s 50-day moving average is $28.06 and its two-hundred day moving average is $27.87. The firm has a market cap of $8.18 billion, a P/E ratio of -10.53 and a beta of 0.93.

Insmed (NASDAQ:INSMGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.16. The company had revenue of $75.50 million for the quarter, compared to analysts’ expectations of $77.76 million. The company’s revenue was up 15.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.17) earnings per share.

Hedge Funds Weigh In On Insmed

A number of hedge funds have recently made changes to their positions in INSM. Vanguard Group Inc. increased its stake in Insmed by 2.7% in the first quarter. Vanguard Group Inc. now owns 14,509,235 shares of the biopharmaceutical company’s stock valued at $393,636,000 after acquiring an additional 383,714 shares during the period. Loomis Sayles & Co. L P grew its stake in shares of Insmed by 47.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 2,383,039 shares of the biopharmaceutical company’s stock valued at $60,172,000 after purchasing an additional 769,443 shares during the period. RTW Investments LP raised its holdings in shares of Insmed by 86.5% in the 3rd quarter. RTW Investments LP now owns 1,865,108 shares of the biopharmaceutical company’s stock worth $47,094,000 after buying an additional 865,108 shares in the last quarter. Capital International Investors bought a new position in shares of Insmed during the 1st quarter worth approximately $43,973,000. Finally, Norges Bank acquired a new stake in Insmed in the 4th quarter valued at $45,029,000.

Insider Activity at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 21,195 shares of the firm’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $55.00, for a total value of $1,165,725.00. Following the sale, the insider now directly owns 106,134 shares in the company, valued at approximately $5,837,370. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Insmed news, insider Martina M.D. Flammer sold 21,195 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $55.00, for a total value of $1,165,725.00. Following the completion of the sale, the insider now owns 106,134 shares in the company, valued at approximately $5,837,370. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sara Bonstein sold 11,088 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $25.32, for a total value of $280,748.16. Following the sale, the chief financial officer now owns 117,481 shares in the company, valued at $2,974,618.92. The disclosure for this sale can be found here. Insiders sold a total of 295,842 shares of company stock worth $13,762,062 in the last ninety days. 4.60% of the stock is currently owned by insiders.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

See Also

Earnings History and Estimates for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.